You are on page 1of 2

RESEARCH NOTE EPIDEMIOLOGY

Laboratory-acquired Vibrio cholerae O1 of 11 cases of cholera were reported to the public health
infection in Austria, 2008 authorities. In all but one case, cholera infection was
acquired during foreign travel. This report concerns the first
Steliana Huhulescu, Eva Leitner, Gebhard Feierl and Franz
case of indigenous cholera reported in Austria for more than
Allerberger
50 years.
Austrian Agency for Health and Food Safety (AGES), National Reference In April 2008, the National Reference Centre for Vibrio
Centre for Vibrio cholerae, Vienna, Austria cholerae received an isolate cultured from the stool specimen
of a patient consulting a general practitioner because of
watery diarrhoea. The 23-year-old microbiology student,
Abstract who had been working with viable V. cholerae for 4 weeks in
a practical laboratory course, asked her general practitioner
Vibrio cholerae infection is a rare but well-documented cause of to consider V. cholerae as a possible causative agent.
laboratory-associated illness. We report on the first case of Three days later, the isolate was reported to be V. chole-
indigenous cholera documented in Austria after more than rae O1, serotype Ogawa, sensitive to ampicillin, ciprofloxa-
fifty years. In April 2008, the National Reference Centre for cin, tetracycline, gentamicin and cefotaxime, and resistant to
V. cholerae received an isolate of V. cholerae O1, serotype trimethoprim. The diarrhoea ceased spontaneously after
Ogawa, cultured from the stool specimen of a patient consulting 3 days, hours before ciprofloxacin therapy was initiated (oral
a general practitioner because of watery diarrhea. The 23 year ciprofloxacin, 250 mg every day for 5 days). The patient had
old microbiology student had been working with viable V. cho-
not been abroad for more than 6 months prior to the onset
lerae for 4 weeks in a practical laboratory course. Two days
of illness. She had no concomitant comedication and had
before onset of symptoms an open 300 mL Erlenmeyer flask
never taken proton-pump inhibitors. (The risk of infection
with approx. 30 mL of overnight V. cholerae culture tipped over following oral exposure may be increased in achlorhydric
and spilled into a laboratory shaker near the student’s working
individuals [2,3].)
place. Wearing gloves and protective gowns, the student and The incubation period of cholera is estimated to range
her supervisor immediately cleaned and decontaminated the
from a few hours to 5 days, and is usually 2–3 days [4]. No
shaker. As a consequence of this laboratory incident, the insti-
specific event explaining this infection in Austria is known.
tution in question replaced the clamp-less shaker plate by a
Pipetting by mouth can be excluded as the cause of infection.
traditional shaker plate with mechanical clamps.
Pipetting by mouth of any infectious material should be
strictly prohibited.
Contact with non-intact skin or mucosa and ingestion
have previously been described as routes of laboratory-asso-
Keywords: Cholera, clamp-less shaker, laboratory-acquired
ciated infection with V. cholerae [5]. Two days before onset
infection, laboratory shaker, Vibrio cholerae
of the symptoms, an open 300-mL Erlenmeyer flask contain-
ing c. 30 mL of an overnight V. cholerae culture tipped over
Original Submission: 14 July 2009; Revised Submission:
and spilled into a laboratory shaker near the student’s work-
19 August 2009; Accepted: 27 August 2009
place. Wearing gloves and protective gowns, the student and
Editor: D. Raoult
her supervisor immediately cleaned and decontaminated the
Article published online: 3 September 2009
shaker. Whether the flask tipped over spontaneously or was
inadvertently pushed over (perhaps when another flask was
removed) could not be ascertained in retrospect. In the
Clin Microbiol Infect 2010; 16: 1303–1304
reported event, a completely new laboratory shaker, with
10.1111/j.1469-0691.2009.03051.x
adhesive mats instead of clamps for holding the flasks, was
Corresponding author and reprint requests: F. Allerberger,
used. In order to limit the possibility of mishandling of bio-
Austrian Agency for Health and Food Safety (AGES), National safety level 2 (BSL2) organisms, any new laboratory machine
Reference Centre for Vibrio cholerae, Währingerstr. 25a, 1090 Vienna, should be assessed for maximally secure handling.
Austria
As a consequence of this laboratory incident, the institu-
E-mail: Franz.Allerberger@ages.at
tion in question replaced the clampless shaker plate with a
traditional shaker plate with mechanical clamps.
In Austria, epidemic cholera has not occurred since 1950 Laboratory-acquired infections are important for evaluat-
(start of statutory reporting) [1]. During 1990–2009, a total ing the effectiveness of biosafety measures.

ª2010 The Authors


Journal Compilation ª2010 European Society of Clinical Microbiology and Infectious Diseases
1304 Clinical Microbiology and Infection, Volume 16 Number 8, August 2010 CMI

BSL2 practices, BSL2 containment equipment and BSL2 2. Giannella RA, Broitman SA, Zamcheck N. Influence of gastric acidity
on bacterial and parasitic enteric infections: a perspective. Ann Intern
facilities are recommended for activities involving cultures of
Med 1973; 78: 271–276.
V. cholerae [6]. V. cholerae infection is a rare but well-docu- 3. Sack GH, Pierce NF, Henessey KN, Mitra RC, Sack RB, Mazumder
mented cause of laboratory-associated illness [7]. This is DNG. Gastric acidity in cholera and noncholera diarrhoea. Bull WHO
rather surprising, as the infectious dose is fairly high. In stud- 1972; 47: 31–36.
4. Heymann DL. Control of communicable diseases manual. Washington,
ies with human volunteers, the infectious dose was deter- DC: American Public Health Association, 2008.
mined to range from 106 to 1011 CFUs [5,6,8,9]. 5. Sewell DL. Laboratory-associated infections and biosafety. Clin Micro-
In many reports of laboratory-acquired infections, there biol Rev 1995; 8: 389–405.
6. US Department of Health and Human Services, Centers for Disease
has been mention of lack of compliance with biosafety prac-
Control and Prevention, National Institutes of Health. Biosafety in
tices. This observation may be reassuring regarding the effec- microbiological and biomedical laboratories (BMBL), 5th edn. Washington,
tiveness of such practices, at least if they are followed [10]. DC: US Government Printing Office, 2007. Available at: http://
www.cdc.gov/OD/ohs/biosfty/bmbl5/bmbl5toc.htm (last accessed 28
It illustrates that educating laboratory personnel to comply
October 2009) and http://www.sas.org/E-Bulletin/archive/library/
with the rules remains the top priority [10]. According to BMBL/secti7c4.htm (last accessed 28 October 2009).
BSL2 criteria, all work that may create aerosols or splatter 7. Sheehy TW, Sprinz H, Augerson WS, Formal SB. Laboratory Vibrio
must be performed inside a biological safety cabinet [6]. cholerae infection in the United States. JAMA 1966; 197: 99–104.
8. Bennish ML. Cholera: pathophysiology clinical features, treatment. In:
These precautions were apparently not taken in the present Wachsmuth KI, Blake PA, Olsik O, eds. Vibrio cholerae and cholera:
case, where an open 300-mL Erlenmeyer flask containing molecular to global perspectives. Washington, DC: American Society
c. 30 mL of overnight culture of V. cholerae was placed in a for Microbiology, 1994; 229–255.
9. Cash RA, Music SI, Libonati JP, Snyder MJJ, Wenzel RP, Hornick RB.
clampless shaker in the laboratory.
Response of man to infection with Vibrio cholerae. I. Clinical, serologi-
cal, and bacteriologic responses to known inoculum. J Infect Dis 1974;
129: 45–52.
Transparency Declaration 10. Kimman TG, Smit E, Klein MR. Evidence-based biosafety: a review
of the principles and effectiveness of microbiological containment
measures. Clin Microbiol Rev 2008; 21: 403–425.
All authors declare no conflicts of interest.

References

1. Huhulescu S, Indra A, Feierl G et al. Occurrence of Vibrio cholerae se-


rogroups other than O1 and O139 in Austria. Wien Klin Wochenschr
2007; 119: 235–241.

ª2010 The Authors


Journal Compilation ª2010 European Society of Clinical Microbiology and Infectious Diseases, CMI, 16, 1303–1304

You might also like